RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC
Journal of Thoracic Oncology · 2025-04 · 20 (4) · 487-499
DOI: 10.1016/j.jtho.2024.11.032 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Thoracic Oncology, 2025-04. Verfasst von Kazuhiko Nakagawa und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka Japan. Electronic address: nakagawa@med.kindai.ac.jp. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Erlotinib Hydrochloride, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
INTRODUCTION: RELAY, a global double-blind, placebo-controlled phase 3 study (NCT02411448) found statistically significant improvement in progression-free survival (primary end point) for ramucirumab (RAM) plus erlotinib (ERL) (RAM + ERL) in patients with untreated EGFR-mutated metastatic NSCLC (hazard ratio [HR] = 0.59, 95% confidence interval [CI]: 0.46-0.76, p 50% received osimertinib in comparable numbers between arms). The safety profile for RAM + ERL was consistent with previous reports with no increased toxicity over time or new safety signals observed. CONCLUSION: In RELAY, OS was not significantly improved with similar long OS durations in both treatment arms. CLINICAL TRIAL INFORMATION: ClinicalTrials.gov Identifier: NCT02411448.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka Japan. Electronic address: nakagawa@med.kindai.ac.jp.
- Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Translational Research in Oncology US Network, Los Angeles, California.
- NHO Kyushu Cancer Center, Fukuoka, Japan.
- Department of Thoracic Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
- Hospital Universitario 12 de Octubre, Madrid, Spain.
- Taipei Cancer Center, Taipei Medical University Hospital, and College of Medicine, Taipei Medical University, Taipei, Taiwan.
Förderung
- Eli Lilly and Company
Zitieren
APA
Nakagawa, K., Garon, E. B., Seto, T., Nishio, M., Aix, S. P., Paz-Ares, L., Chiu, C. H., Park, K., Novello, S., Nadal, E., Nishino, K., Yoh, K., Shih, J. Y., Chik, J. Y. K., Moro-Sibilot, D., Puri, T., Chacko Varughese, S., Frimodt-Moller, B., Visseren-Grul, C., & Reck, M. (2025). RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC. Journal of Thoracic Oncology, 20(4), 487-499. https://doi.org/10.1016/j.jtho.2024.11.032
Vancouver
Nakagawa K, Garon EB, Seto T, Nishio M, Aix SP, Paz-Ares L, et al. RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC. Journal of Thoracic Oncology. 2025;20(4):487-499. doi:10.1016/j.jtho.2024.11.032
BibTeX
@article{Nakagawa2025,
author = {Nakagawa, Kazuhiko and Garon, Edward B and Seto, Takashi and Nishio, Makoto and Aix, Santiago Ponce and Paz-Ares, Luis and Chiu, Chao-Hua and Park, Keunchil and Novello, Silvia and Nadal, Ernest and Nishino, Kazumi and Yoh, Kiyotaka and Shih, Jin-Yuan and Chik, Jeannie Y K and Moro-Sibilot, Denis and Puri, Tarun and Chacko Varughese, Sunoj and Frimodt-Moller, Bente and Visseren-Grul, Carla and Reck, Martin},
title = {RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC},
journal = {Journal of Thoracic Oncology},
year = {2025},
volume = {20},
number = {4},
pages = {487--499},
doi = {10.1016/j.jtho.2024.11.032}
}
EUVIMED